Avoid common mistakes on your manuscript.
With great interest we read the recent article by Reintam Blaser et al. describing the current status of managing acute mesenteric ischemia (AMI) in the critically ill patient [1]. We would like to congratulate the authors for their thorough and balanced review of the present diagnostic and therapeutic options in these patients and especially agree on the importance of further research in exploring the least understood AMI entity associated with the highest mortality, namely non-occlusive mesenteric ischemia (NOMI).
Traditionally linked primarily with post-cardiac surgery patients, our group, along with others, has more recently shown that NOMI can also occur in diverse medical intensive care patients with septic shock and multi-organ failure [2, 3]. Early diagnosis of NOMI remains very challenging given the lack of biomarkers and specific clinical signs in critically ill, non-awake patients. However, we recently identified unclear rapid deterioration of organ-function and vasopressor dose as earlier clinical signs than ischemic injury-related markers such as transaminases, creatine-kinase or lactic acid dehydrogenase [2]. Treatment of NOMI beyond correcting hypovolemia and cardiac output remains equally challenging.
In our experience, patients diagnosed with potential additional NOMI, especially those presenting with septic shock and multi-organ failure, often exhibit high levels of instability, rendering abdominal exploration for surgeons exceptionally challenging. As an alternative, intra-arterial vasodilatory therapy directly in the superior mesenteric artery has been explored for a long time as a minimal-invasive approach to improve splanchnic perfusion [4]. In the absence of randomized controlled studies, comparative analyses have repeatedly demonstrated a potential survival benefit in patients undergoing additive intra-arterial vasodilatory therapy when compared to conservative therapy alone [2, 4, 5]. Our group has prospectively investigated potential predictors of response to intra-arterial vasodilatory therapy using both clinical as well as perfusion angiography data [3]. This study identified a reduction of serum lactate concentration of more than 2 mmol/l in the first 24 h after the intervention as a strong predictor of treatment success, e.g. patients with such a lactate reduction had a 26% lower mortality (59% vs. 85%) [3]. Measurement of non-routine biomarkers of intestinal ischemia at study inclusion revealed that transmural ischemia might be already present in most of these patients although computed tomography contrast imaging did not indicate any signs of transmural necrosis at this time, likely further indicating the therapeutic dilemma still seen in these patients.
Does NOMI remain an untreatable disease in the critically ill?
Robert Kennedy said once: “Some men see things as they are and ask, “Why?” I dream things that never were and ask, “Why not?”. Let us collaborate to enhance our capabilities in comprehending, diagnosing and treating NOMI in critically ill patients.
Availability of data and materials
Not applicable.
References
Reintam Blaser A, Coopersmith CM, Acosta S (2024) Managing acute mesenteric ischaemia. Intensive Care Med. https://doi.org/10.1007/s00134-024-07363-1
Stahl K, Busch M, Maschke SK, Schneider A, Manns MP, Fuge J et al (2020) A retrospective analysis of nonocclusive mesenteric ischemia in medical and surgical ICU patients: clinical data on demography, clinical signs, and survival. J Intensive Care Med 35(11):1162–1172
Rittgerodt N, Pape T, Busch M, Becker LS, Schneider A, Wedemeyer H et al (2022) Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study. Crit Care 26(1):92
Stahl K, Rittgerodt N, Busch M, Maschke SK, Schneider A, Manns MP et al (2020) Nonocclusive mesenteric ischemia and interventional local vasodilatory therapy: a meta-analysis and systematic review of the literature. J Intensive Care Med 35(2):128–139
Winzer R, Fedders D, Backes M, Ittermann T, Gründling M, Mensel B et al (2020) Local intra-arterial vasodilator infusion in non-occlusive mesenteric ischemia significantly increases survival rate. Cardiovasc Intervent Radiol 43(8):1148–1155
Acknowledgements
Not applicable.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Contributions
KS, CB and SD wrote the manuscript. All authors approved the final version of the manuscript.
Corresponding author
Ethics declarations
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This comment refers to the article available online at https://doi.org/10.1007/s00134-024-07363-1
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Stahl, K., Bode, C. & David, S. Non-occlusive mesenteric ischemia and intra-arterial vasodilatory therapy in severe shock and multi-organ failure: treating the untreatable?. Intensive Care Med 50, 792–793 (2024). https://doi.org/10.1007/s00134-024-07403-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-024-07403-w